Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. on January 16, 2023. The filing discloses amendments to service agreements for key members of the management team (Vorstand) of Immunic AG, a wholly-owned subsidiary of the Company. Under German law, this management team oversees the daily business of the subsidiary.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes and Executive Compensation
Effective January 1, 2023, the Company entered into fourth addendums to the service agreements of three executives, extending their service on the Immunic AG management team through December 31, 2023. The compensation changes are as follows:
- Dr. Daniel Vitt (CEO and President): Annual salary increased to EUR 543,166, with a targeted yearly bonus of up to EUR 271,583.
- Dr. Andreas Muehler (Chief Medical Officer): Annual salary set at EUR 223,768, with a targeted yearly bonus of up to EUR 89,507.20.
- Dr. Hella Kohlhof (Chief Scientific Officer): Annual salary set at EUR 380,069, with a targeted yearly bonus of up to EUR 152,027.60.
All salaries are payable in 12 monthly installments. Bonuses are contingent upon the achievement of certain targets.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. The document serves solely to disclose the amended employment terms and incorporates the full agreements as Exhibits 10.1, 10.2, and 10.3.
Key Facts for Investor Verification
- Verify the specific performance targets required to achieve the targeted bonuses for Dr. Vitt, Dr. Muehler, and Dr. Kohlhof by reviewing the attached Exhibits 10.1, 10.2, and 10.3.
- Confirm the total annual cash compensation obligation for the three executives totals approximately EUR 1.14 million in base salary plus up to EUR 513,117.80 in potential bonuses.
- Note that these agreements extend the tenure of the management team only through December 31, 2023, requiring future action for renewal.